Scilex Holding Company Announces Results From Market Research With Rheumatologists Reveal A High Degree Of Interest In Gloperba As A Liquid Colchicine Formulation Designed For Precision Dosing
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company announced strong interest from rheumatologists in Gloperba, a liquid colchicine for gout prophylaxis, due to its precision dosing. Gloperba targets patients with comorbid conditions and those experiencing gastrointestinal side effects. Scilex, with a robust distribution network and experienced commercial team, is discussing dosing recommendations with the FDA. The gout treatment market is expected to reach $2.0 billion by 2028 in the U.S.
December 19, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex's Gloperba has garnered significant interest from rheumatologists for its precision dosing, addressing a need in the gout treatment market. The company's strong distribution network and commercial team are positives for the product's market access.
The positive reception of Gloperba by rheumatologists suggests a strong market demand, which could lead to increased revenues for Scilex. The company's experience in commercializing similar products and the expected growth of the gout treatment market further support a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100